Daily BNP Injections Show Heart Failure Efficacy in Pilot Clinical Study
Major Finding: Twice-daily subcutaneous injections of B-type natriuretic peptide (nesiritide) led to significant improvements in left ventricular volume and other heart failure measures after 8 weeks.
Data Source: NICE BNP, a randomized, placebo-controlled study of 40 patients with New York Heart Association class II or III heart failure.
Disclosures: The study received partial funding from Scios, which markets nesiritide (Natrecor). Dr. Chen said that he had no other disclosures. Dr. Burnett is chairman of the scientific advisory board of Nile Therapeutics, a company started by the Mayo Clinic to develop novel, therapeutic forms of BNP.
The study received partial funding from Scios, which markets nesiritide (Natrecor). Dr. Chen said that he had no other disclosures. Dr. Burnett is chairman of the scientific advisory board of Nile Therapeutics, a company started by the Mayo Clinic to develop novel, therapeutic forms of BNP.
